NZ583803A - Agents with angiogenic and wound healing activity - Google Patents

Agents with angiogenic and wound healing activity

Info

Publication number
NZ583803A
NZ583803A NZ583803A NZ58380308A NZ583803A NZ 583803 A NZ583803 A NZ 583803A NZ 583803 A NZ583803 A NZ 583803A NZ 58380308 A NZ58380308 A NZ 58380308A NZ 583803 A NZ583803 A NZ 583803A
Authority
NZ
New Zealand
Prior art keywords
angiogenic
agents
wound healing
protein
healing activity
Prior art date
Application number
NZ583803A
Other languages
English (en)
Inventor
Keryn Johnson
Madhusudan Vasudevamurthy
Original Assignee
Ind Res Ltd
Australian Meat & Live Stock
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2007904857A external-priority patent/AU2007904857A0/en
Application filed by Ind Res Ltd, Australian Meat & Live Stock filed Critical Ind Res Ltd
Publication of NZ583803A publication Critical patent/NZ583803A/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Dermatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
NZ583803A 2007-09-07 2008-09-05 Agents with angiogenic and wound healing activity NZ583803A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
AU2007904857A AU2007904857A0 (en) 2007-09-07 Agents with angiogenic and wound healing activity
PCT/AU2008/001319 WO2009029991A1 (en) 2007-09-07 2008-09-05 Agents with angiogenic and wound healing activity

Publications (1)

Publication Number Publication Date
NZ583803A true NZ583803A (en) 2012-12-21

Family

ID=40428369

Family Applications (1)

Application Number Title Priority Date Filing Date
NZ583803A NZ583803A (en) 2007-09-07 2008-09-05 Agents with angiogenic and wound healing activity

Country Status (6)

Country Link
US (1) US8404644B2 (enExample)
EP (2) EP2407175A1 (enExample)
JP (1) JP5685773B2 (enExample)
AU (1) AU2008295449A1 (enExample)
NZ (1) NZ583803A (enExample)
WO (1) WO2009029991A1 (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8404644B2 (en) * 2007-09-07 2013-03-26 Meat & Livestock Australia Limited Agents with angiogenic and wound healing activity
JP2013513622A (ja) * 2009-12-14 2013-04-22 ユニバーシティ オブ マサチューセッツ 白内障及び老眼を阻害する方法
CA2823505A1 (en) * 2011-01-26 2012-08-02 Megmilk Snow Brand Co., Ltd. Agent for improving peripheral sensitivity of skin
WO2013073968A2 (en) * 2011-09-12 2013-05-23 Industrial Research Limited Agents for modulation of cell signalling
JP2014005254A (ja) * 2012-06-26 2014-01-16 Bfsr:Kk 熱傷由来全身性炎症反応症候群の予防外用薬
CN105209033B (zh) 2013-03-14 2018-09-18 马萨诸塞大学 抑制白内障和老花眼的方法
KR20170040648A (ko) * 2015-10-05 2017-04-13 차의과학대학교 산학협력단 당뇨병성 족부궤양의 예방 또는 치료용 약학 조성물
CN108348494A (zh) 2015-11-13 2018-07-31 马萨诸塞大学 用于抑制白内障和老花眼的含peg的双官能分子
US20220088265A1 (en) * 2019-02-08 2022-03-24 Manmeet Kaur Biomaterials and methods related thereto

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2187482A1 (en) * 1995-10-13 1997-04-14 Eri Inoue Pharmaceutical composition
WO1999051634A1 (en) 1998-04-03 1999-10-14 Hunan Medical University Human gap junction protein beta-3
WO1999051738A1 (en) 1998-04-03 1999-10-14 Hunan Medical University Human gap junction protein beta-4
CA2342886A1 (en) 1998-10-15 2000-04-20 E.I. Du Pont De Nemours And Company Polymers, containing a fluorocyclobutyl ring and their preparation
WO2004005883A2 (en) * 2002-07-02 2004-01-15 The Johns Hopkins University Secreted and cytoplasmic tumor endothelial markers
JP3783200B2 (ja) * 2000-08-24 2006-06-07 株式会社加美乃素本舗 血管新生剤
US20030215424A1 (en) 2002-05-15 2003-11-20 Seul Kyung Hwan Method of modulating angiogenesis
US7263214B2 (en) 2002-05-15 2007-08-28 Ge Medical Systems Global Technology Company Llc Computer aided diagnosis from multiple energy images
WO2004096277A1 (ja) * 2003-05-01 2004-11-11 Kyoto University 眼内血管新生疾患の予防又は治療剤
WO2005004894A2 (en) * 2003-05-12 2005-01-20 Expressive Constructs, Inc. Methods for increasing cell and tissue viability
CA2573720A1 (en) * 2004-07-14 2006-02-23 University Of Utah Research Foundation Netrin-related compositions and uses
EP2662088A3 (en) 2005-02-03 2014-02-19 Coda Therapeutics Limited Anti-connexin compounds and uses thereof
US7897581B2 (en) 2005-02-24 2011-03-01 Massachusetts Eye & Ear Infirmary Methods and compounds for promoting vessel regression
EP1978988A4 (en) 2006-01-13 2009-11-04 Univ New York State Res Found PEPTIDE-BASED REGULATION OF GAP-JUNCTIONS
WO2008005021A1 (en) * 2006-06-30 2008-01-10 The Johns Hopkins University Use of crystallin for the modulation of angiogenesis
JP5960944B2 (ja) 2006-11-15 2016-08-02 コーダ セラピューティクス， インコーポレイテッド 創傷治癒のための改善された方法および組成物
JP2010512403A (ja) 2006-12-11 2010-04-22 ザ ボード オブ トラスティーズ オブ ザ リーランド スタンフォード ジュニア ユニバーシティ 炎症の治療法としてのαＢクリスタリン
WO2009012224A2 (en) 2007-07-13 2009-01-22 The Research Foundation Of State University Of New York Peptide-based regulation of gap junctions
US8404644B2 (en) * 2007-09-07 2013-03-26 Meat & Livestock Australia Limited Agents with angiogenic and wound healing activity

Also Published As

Publication number Publication date
EP2190455A4 (en) 2010-11-24
US20100210531A1 (en) 2010-08-19
AU2008295449A1 (en) 2009-03-12
JP2010538020A (ja) 2010-12-09
EP2407175A1 (en) 2012-01-18
EP2190455A1 (en) 2010-06-02
EP2407175A9 (en) 2012-02-29
US8404644B2 (en) 2013-03-26
WO2009029991A1 (en) 2009-03-12
JP5685773B2 (ja) 2015-03-18

Similar Documents

Publication Publication Date Title
BR112013028914A2 (pt) antagonistas de receptores de integrina e seus métodos de uso
EP3195868A3 (en) Therapeutic use of a tlr agonist and combination therapy
NZ707377A (en) Combination therapy methods for treating proliferative diseases
NZ606825A (en) Methods and compositions for treating complement-associated disorders
EA201100335A8 (ru) Производные пурина для применения при лечении связанных с fab заболеваний
WO2009156735A3 (en) New therapeutic agents
NZ603319A (en) Diabetes therapy
IL201479A (en) Use of tapentadol for the preparation of pain medication
WO2009065093A3 (en) Use of stem cells for wound healing
NZ608502A (en) Polypeptides that bind to human complement component c5
NZ600583A (en) Visfatin therapeutic agents for the treatment of acne and other conditions
TW200616608A (en) Memantine as adjunctive treatment to atypical antipsychotics in schizophrenia patients
NZ595376A (en) Dental anesthetic comprising tetracaine and a vasoconstrictor for intranasal administration
MX2009011900A (es) Curacion de herida diabetica.
NZ591525A (en) Methods of treatment of complicated skin and skin structure infections using single doses of oritavancin
WO2005007072A3 (en) Methods and pharmaceutical compositions for healing wounds
PH12014500250A1 (en) Substituted 3-(biphenyl-3-yl)-4 -hydroxy-8-methoxy-1-azaspiro[4.5]dec-3-en-2-one
CO6361995A2 (es) Derivados de isoquinolinona como antagonistas de nk3
IL205290A (en) A variant of human neurorthin protein, or its active biological part, containing medicinal preparations, and its use in the preparation of therapeutic drugs
MX341660B (es) Agonista del receptor de ghrelina para el tratamiento de caquexia.
EP4196049A4 (en) LARGE THICKNESS, ANATOMY-SPECIFIC CRANIOFACIAL IMPLANTS FOR COMBINED HARD AND SOFT TISSUE RECONSTRUCTION USING INTEGRATED DRUG DELIVERY TECHNOLOGY
MX2010006724A (es) Regimenes terapeuticos para el tratamiento de desordenes inmunoinflamatorios.
NZ604009A (en) A combination composition comprising ibuprofen and paracetamol
MX2009008873A (es) Composicion util para el tratamiento de diabetes tipo 2.
WO2022019839A8 (en) Crystalline zirconium phosphate for use in therapy, pharmaceutical composition, and use of the same

Legal Events

Date Code Title Description
PSEA Patent sealed
RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 3 YEARS UNTIL 05 SEP 2015 BY AJ PARK

Effective date: 20130604

ERR Error or correction

Free format text: THE OWNER HAS BEEN CORRECTED TO 943419, MEAT + LIVESTOCK AUSTRALIA LIMITED, LEVEL 1, 165 WALKER STREET, NORTH SYDNEY, NSW 2060, AU; 3037568, INDUSTRIAL RESEARCH LIMITED, GRACEFIELD RESEARCH CENTRE, 69 GRACEFIELD ROAD, LOWER HUTT, NZ

Effective date: 20140114

LAPS Patent lapsed